Berlin - Delayed Quote EUR

BioXcel Therapeutics Inc (BX2.BE)

Compare
0.3046
-0.0065
(-2.09%)
As of 8:00:48 AM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,276.0000
1,380.0000
375.0000
--
--
Cost of Revenue
2,025.0000
1,260.0000
20.0000
--
--
Gross Profit
251.0000
120.0000
355.0000
--
--
Operating Expense
74,469.0000
167,739.0000
160,000.0000
106,936.0000
82,297.0000
Operating Income
-74,218.0000
-167,619.0000
-159,645.0000
-106,936.0000
-82,297.0000
Net Non Operating Interest Income Expense
-11,352.0000
-7,665.0000
-5,685.0000
4.0000
128.0000
Other Income Expense
14,574.0000
-3,769.0000
-427.0000
--
155.0000
Pretax Income
-70,996.0000
-179,053.0000
-165,757.0000
-106,932.0000
-82,169.0000
Net Income Common Stockholders
-70,996.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Diluted NI Available to Com Stockholders
-70,996.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Basic EPS
-2.04
-6.15
-5.92
-4.05
-3.79
Diluted EPS
-2.04
-6.15
-5.92
-4.05
-3.79
Basic Average Shares
35,749.2500
29,129.0000
28,015.0000
26,373.0000
21,683.0000
Diluted Average Shares
35,749.2500
29,129.0000
28,015.0000
26,373.0000
21,683.0000
Total Operating Income as Reported
-76,627.0000
-171,782.0000
-159,645.0000
-106,935.0000
-82,297.0000
Total Expenses
76,494.0000
168,999.0000
160,020.0000
106,936.0000
82,297.0000
Net Income from Continuing & Discontinued Operation
-70,996.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Normalized Income
-68,587.0000
-174,890.0000
-165,757.0000
-106,931.0000
-82,169.0000
Interest Income
3,180.0000
5,649.0000
2,528.0000
44.0000
155.0000
Interest Expense
14,532.0000
13,314.0000
8,213.0000
40.0000
27.0000
Net Interest Income
-11,352.0000
-7,665.0000
-5,685.0000
4.0000
128.0000
EBIT
-56,464.0000
-165,739.0000
-157,544.0000
-106,892.0000
-82,142.0000
EBITDA
-56,154.0000
-165,421.0000
-157,217.0000
-106,595.0000
-81,954.0000
Reconciled Cost of Revenue
2,025.0000
1,260.0000
20.0000
--
--
Reconciled Depreciation
310.0000
318.0000
327.0000
297.0000
188.0000
Net Income from Continuing Operation Net Minority Interest
-70,996.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Total Unusual Items Excluding Goodwill
-2,409.0000
-4,163.0000
--
--
155.0000
Total Unusual Items
-2,409.0000
-4,163.0000
--
--
155.0000
Normalized EBITDA
-53,745.0000
-161,258.0000
-157,217.0000
-106,595.0000
-81,954.0000
12/31/2020 - 3/12/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

0M4.DU Mersana Therapeutics Inc
0.6036
+2.20%
 
3G0.BE Altimmune Inc
6.70
-0.21%
 
M55.F MacroGenics, Inc.
2.8800
-0.48%
 
AT20.F Atara Biotherapeutics, Inc.
8.05
+8.05%
 
NV4.F Cellectar Biosciences, Inc.
0.2160
+8.00%
 
NV4.MU Cellectar Biosciences Inc
0.2420
0.00%
 
1VT.DU Viking Therapeutics Inc
32.57
+1.31%
 
2UV.DU Applied Therapeutics Inc
0.5570
-3.05%
 
2UV.F Applied Therapeutics, Inc.
0.5465
+6.12%
 
8AW0.BE Ocean Biomedical Inc
0.1810
0.00%